CAJ | 학술논문

目的：评估氨磺必利对阿尔茨海默病患者行为和精神症状的疗效及安全性。方法将88例伴有行为和精神症状的阿尔茨海默病患者随机分为氨磺必利组和奥氮平组，分别接受12周的氨磺必利或奥氮平系统治疗。在治疗前后分别采用阿尔茨海默病行为病理量表（ BEHAVE-AD ）、阳性和阴性综合征量表（ PANSS ）、简易精神状况检查量表（ MMSE）、日常生活能力量表（ ADL）、治疗中需处理的不良反应症状量表（ TESS）评估疗效和安全性，在治疗前后分别测定空腹血糖、总胆固醇、高密度脂蛋白、低密度脂蛋白、甘油三酯及体质量指数。结果治疗后，两组有效率比较差异无统计学意义（P＞0．05）；两组治疗后ADL评分、BEHAVE-AD总分及各因子分、PANSS总分及各因子分均低于治疗前（P＜0．05），治疗后PANSS阴性症状评分氨磺必利组低于奥氮平组（P＜0．05）；治疗后氨磺必利组的BMI、FBS、LDL、TC、TG均低于奥氮平组（P＜0．05），治疗后氨磺必利组嗜睡、视物模糊、头晕、便秘及体质量增加发生率低于奥氮平组（P＜0．05）。结论氨磺必利对阿尔茨海默病伴行为和精神症状的疗效与奥氮平相当，但氨磺必利不良反应发生率低，对患者血糖、血脂的影响较小。
목적：평고안광필리대아이자해묵병환자행위화정신증상적료효급안전성。방법장88례반유행위화정신증상적아이자해묵병환자수궤분위안광필리조화오담평조，분별접수12주적안광필리혹오담평계통치료。재치료전후분별채용아이자해묵병행위병리량표（ BEHAVE-AD ）、양성화음성종합정량표（ PANSS ）、간역정신상황검사량표（ MMSE）、일상생활능역량표（ ADL）、치료중수처리적불량반응증상량표（ TESS）평고료효화안전성，재치료전후분별측정공복혈당、총담고순、고밀도지단백、저밀도지단백、감유삼지급체질량지수。결과치료후，량조유효솔비교차이무통계학의의（P＞0．05）；량조치료후ADL평분、BEHAVE-AD총분급각인자분、PANSS총분급각인자분균저우치료전（P＜0．05），치료후PANSS음성증상평분안광필리조저우오담평조（P＜0．05）；치료후안광필리조적BMI、FBS、LDL、TC、TG균저우오담평조（P＜0．05），치료후안광필리조기수、시물모호、두훈、편비급체질량증가발생솔저우오담평조（P＜0．05）。결론안광필리대아이자해묵병반행위화정신증상적료효여오담평상당，단안광필리불량반응발생솔저，대환자혈당、혈지적영향교소。
Objective To explore the efficacy and safety of amisulpride in treatment of Alzheimer's patients with behavioral and psychological symptoms.Methods A total of 88 Alzheimer's Patients with behavioral and psychological symptoms were randomly divided into amisulpride group with amisulpride and olanzapine group with olanzapine for 12 weeks of treatment.They were assessed with the Behavioral Pathology in Alzheimer's Disease Rating Scale ( BEHAVE-AD ) , Positive and Negative Syndrome Scale( PANSS) , Mini-mental State Examination ( MMSE) , Activity of Daily Living Scale( ADL) , Treatment Emergent Symptom Scale (TESS) and examined with the fasting blood glucose (FBG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), body mass index (BMI) before and after treatment.Results After treatment, there was no difference for the effective rate between two groups (P>0.05).After treatment, the scores of ADL, the total and all factors scores of BEHAVE-AD and PANSS in two groups were all significantly lower than those before treatment (P<0.05).After treatment, the negative factor scores of PANSS in amisulpride group were significantly lower than those in olanzapine group (P <0.05).After treatment, the levels of BMI, FBS, LDL, TC,TG in amisulpride group were all significantly lower than those in olanzapine group (P<0.05).After treatment, the incidence rates of drowsiness,blurred vision,dizziness,constipation and body mass increase in amisulpride group were all significantly lower than those in olanzapine group (P<0.05).Conclusion It's effective for amisulpride and olanzapine in the treatment of Alzheimer's patients with behavioral and psychological symptoms, but there are little side effects and the negative influence of glucose and lipid metabolism for amisulpride.